tradingkey.logo

J.P. Morgan initiates coverage of Aktis Oncology with 'overweight' rating

ReutersFeb 3, 2026 4:01 PM

J.P. Morgan initiates coverage of Aktis Oncology AKTS.O with "overweight" rating; sets PT of $30

Brokerage lauds cancer drug developer's platform for developing radiopharmaceutical therapies, which are a novel means of delivering targeted radiation for cancer

"We see the RPT modality taking off in the coming years and see Aktis entering at a sweet spot where it can both leverage past learnings in the space while also being early enough to be positioned to develop first-in-class products in a relatively open field," says JPM

Including session's move, AKTS is down 20.9% since its debut on January 9

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI